From the Departments of Clinical Pharmacy & Toxicology and.
Medical Statistics, Leiden University Medical Centre, Leiden, the Netherlands.
Cancer J. 2019 Mar/Apr;25(2):116-120. doi: 10.1097/PPO.0000000000000370.
Transcriptome signature reversion (TSR) has been hypothesized as a promising method for discovery and use of existing noncancer drugs as potential drugs in the treatment of cancer (i.e., drug repositioning, drug repurposing). The TSR assumes that drugs with the ability to revert the gene expression associated with a diseased state back to its healthy state are potentially therapeutic candidates for that disease. This article reviews methodology of TSR and critically discusses key TSR studies. In addition, potential conceptual and computational improvements of this novel methodology are discussed as well as its current and possible future application in precision oncology trials.
转录组特征回复（TSR）被假设为一种有前途的方法，用于发现和利用现有的非癌症药物作为治疗癌症的潜在药物（即药物重定位，药物再利用）。TSR 假设，具有将与疾病状态相关的基因表达恢复到健康状态的能力的药物可能是该疾病的治疗候选药物。本文综述了 TSR 的方法学，并对关键的 TSR 研究进行了批判性讨论。此外，还讨论了这种新方法的潜在概念和计算改进，以及其在精准肿瘤学试验中的当前和可能的未来应用。
